SPRINT. Counteracting the risk of prehypertension?
| dc.contributor.author | Ruilope Urioste, Luis Miguel | |
| dc.date.accessioned | 2016-06-04T13:14:05Z | |
| dc.date.available | 2016-06-04T13:14:05Z | |
| dc.date.issued | 2016 | |
| dc.description.abstract | The SPRINT trial1 has raised the possibility that systolic blood pressure (BP) values <120 mm Hg constitute the future goal for high-risk hypertensive patients. At baseline, around 50% of the patients were within the frame of prehypertension, whereas the remaining were hypertensive after an unusual but reliable (for daily clinical practice standard) measurement of office BP. Prehypertension is characterized by an increased cardiovascular risk, particularly in Stage 2 (systolic BP: 130–139 mm Hg) that can attain 40% at 10 years if established cardiovascular disease, diabetes, or both are presented. | spa |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 3.263 JCR (2016) Q2, 24/63 Peripheral Vascular Disease | spa |
| dc.description.sponsorship | Sin financiación | spa |
| dc.identifier.citation | Ruilope, L. M. (2016). SPRINT. Counteracting the risk of prehypertension?. Journal of the American Society of Hypertension, 10(7), 546-547. DOI: 10.1016/j.jash.2016.05.003 | spa |
| dc.identifier.doi | 10.1016/j.jash.2016.05.003 | spa |
| dc.identifier.issn | 19331711 | |
| dc.identifier.uri | http://hdl.handle.net/11268/5201 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights.accessRights | restricted access | spa |
| dc.subject.other | Hipertensión arterial | spa |
| dc.subject.other | SPRINT trial | spa |
| dc.subject.uem | Hipertensión - Tratamiento | spa |
| dc.subject.unesco | Sistema cardiovascular | spa |
| dc.title | SPRINT. Counteracting the risk of prehypertension? | spa |
| dc.type | journal article | spa |
| dspace.entity.type | Publication |